AbbVie Inc. (TSX:ABBV)
Canada · Delayed Price · Currency is CAD | Market Cap | 655.23B +42.3% |
| Revenue (ttm) | 87.69B +9.5% |
| Net Income | 5.02B -13.3% |
| EPS | 2.83 -13.2% |
| Shares Out | n/a |
| PE Ratio | 130.57 |
| Forward PE | 17.73 |
| Dividend | 1.19 (3.24%) |
| Ex-Dividend Date | Jul 15, 2026 |
| Volume | 2,300 |
| Open | 36.60 |
| Previous Close | 35.87 |
| Day's Range | 36.60 - 37.14 |
| 52-Week Range | 26.81 - 37.13 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 31, 2026 |
About AbbVie
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medi... [Read more]
Financial Performance
In 2025, AbbVie's revenue was $61.16 billion, an increase of 8.57% compared to the previous year's $56.33 billion. Earnings were $4.19 billion, a decrease of -1.23%.
Financial numbers in USD Financial StatementsNews
AbbVie announces Elahere availability in Singapore
AbbVie (ABBV) announced availability of Elahere in Singapore for the treatment of Platinum-Resistant Ovarian Cancer. Elahere is the first and only antibody-drug conjugate therapy approved specifically...
AbbVie announces European Commission approval for Rinvoq
AbbVie (ABBV) announced that the European Commission has approved Rinvoq for the treatment of adult and adolescent patients 12 years and older with severe alopecia areata. “The European Commission’s a...
AbbVie price target raised to $300 from $275 at Barclays
Barclays raised the firm’s price target on AbbVie (ABBV) to $300 from $275 and keeps an Overweight rating on the shares. The firm adjusted targets in the biopharmaceuticals space as…
AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults and Adolescents with Severe Alopecia Areata
RINVOQ ® is now approved in the European Union for the treatment of adult and adolescent patients with severe alopecia areata (AA) Approval was based on the pivotal Phase 3 UP-AA clinical program, whi...
AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults and Adolescents with Non-Segmental Vitiligo
RINVOQ is the first and only systemic medication approved in the European Union to treat adult and adolescent patients with non-segmental vitiligo (NSV) The approval is supported by data from the Phas...
Genmab, AbbVie provide clarification on Phase 3 EPCORE(R) DLBCL-1 trial
Genmab A/S (GMAB) and AbbVie (ABBV) provided clarification on the primary endpoints from the Phase 3 EPCORE(R) DLBCL-1 study evaluating monotherapy epcoritamab (DuoBody(R)-CD3xCD20), a T-cell engaging...
Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
COPENHAGEN, Denmark & NORTH CHICAGO, Ill.--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) and AbbVie (NYSE: ABBV) today provided clarification on the primary endpoints from the Phase 3 EPCORE® DLBCL-1 stu...
AbbVie price target raised to $282 from $273 at Canaccord
Canaccord raised the firm’s price target on AbbVie (ABBV) to $282 from $273 and keeps a Buy rating on the shares. The firm updated its model ahead of Q2 results…
AbbVie’s Allergan Aesthetics receives approval for Boey in Europe
Allergan Aesthetics announced the European Commission has approved Boey in Europe, for the temporary improvement in the appearance of moderate to severe lines between the eyebrows seen at maximum frow...
Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE), for use in Europe: the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients
Boey® is the first and only rapid-onset and short-duration botulinum neurotoxin serotype E approved in Europe that adult patients can try for the temporary improvement of glabellar lines¹ Results may ...
AbbVie price target raised to $260 from $230 at Citi
Citi analyst Geoff Meacham raised the firm’s price target on AbbVie (ABBV) to $260 from $230 and keeps a Neutral rating on the shares. The firm adjusted targets in the…
SkinMedica® Deepens Commitment to Regenerative Science with Continued Investment in Research and Development
SkinMedica ® launches Regenerative Science Advisory Board to shape future innovation Expands its state-of-the-art research and development (R&D) facility to support the next generation of science-led ...
Big Pharma's $300 Billion Patent Problem Fuels Biotech Deals
Big Pharma has a $300 billion problem, and biotech developers with promising drugs are becoming the fix. Major drugmakers are spending at a pace not seen since 2019 to replace medicines that will soon...
AbbVie price target raised to $260 from $230 at UBS
UBS raised the firm’s price target on AbbVie (ABBV) to $260 from $230 and keeps a Neutral rating on the shares.
AbbVie price target raised to $300 from $258 at BMO Capital
BMO Capital raised the firm’s price target on AbbVie (ABBV) to $300 from $258 and keeps an Outperform rating on the shares as part of a broader research note previewing…
2 ‘Strong Buy’ Dividend Aristocrat Stocks to Grab Right Now for August Payouts
AbbVie ($ABBV) and Abbott Laboratories ($ABT) are two Dividend Aristocrat stocks with a Strong Buy consensus rating on Wall Street and an ex-dividend date of July 15, according to the…
AbbVie price target raised to $280 from $260 at RBC Capital
RBC Capital raised the firm’s price target on AbbVie (ABBV) to $280 from $260 and keeps an Outperform rating on the shares after its Q2 pre-announcement. Sentiment has changed significantly…
AbbVie price target raised to $276 from $234 at BofA
BofA analyst Tim Anderson raised the firm’s price target on AbbVie (ABBV) to $276 from $234 and keeps a Buy rating on the shares. Second quarter results are expected to…
AbbVie price target raised to $295 from $260 at Wells Fargo
Wells Fargo raised the firm’s price target on AbbVie (ABBV) to $295 from $260 and keeps an Overweight rating on the shares. The firm could see a modest Skyrizi-driven beat…
AbbVie price target raised to $280 from $260 at JPMorgan
JPMorgan raised the firm’s price target on AbbVie (ABBV) to $280 from $260 and keeps an Overweight rating on the shares. The firm, which is anticipating “a largely in-line quarter,”…
AbbVie price target raised to $261 from $249 at Guggenheim
Guggenheim raised the firm’s price target on AbbVie (ABBV) to $261 from $249 and keeps a Buy rating on the shares. The firm updated its model ahead of the Q2…
Buy these quality, low-stress stocks for the summer, says Jefferies
Markets have become more volatile as investors debate whether big tech companies are getting enough return on their AI spending. The S&P 500 momentum index has outperformed the wider market by more th...
AbbVie says Q2 EPS to include unfavorable impact of 17c
In a regulatory filing, AbbVie (ABBV) said that reported GAAP earnings and adjusted non-GAAP earnings for the second quarter of 2026 are expected to include acquired IPR&D and milestones expense…
AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma
TEPKINLY ® (epcoritamab) plus lenalidomide and rituximab (R 2) is the first and only bispecific-based therapy approved in Europe for the treatment of relapsed or refractory follicular lymphoma in the...
US House committee opens investigation into Merck, AbbVie China drug trials
The chair of the U.S. House Select Committee on China opened national security investigations into whether five drugmakers including Merck and AbbVie have been involved in clinical trials conducted i...